NANOterapeutici INnovativi a base di CICLOdestrine (NANOINCICLO)

# Record card
255
Thematic areas
Chemicals & Physics
Materials
Materials / Photo-active & graphene-based materials
Chemicals & Physics / Micro and nanotechnology related to physical, chemical and exact sciences
Health & Biotech
Health & Biotech / Smart Devices for Health and Wellness
Health & Biotech / Nanomedicine
Health & Biotech / Diagnostic, Medical imaging & advanced bioimaging
Health & Biotech / Development of new drugs
Chemicals & Physics / Subtainable substances and green chemistry
Health & Biotech / Medical Device
Description

NANOINCICLO is a technology based on the use of nanostructured cyclodextrins (CDs) for the targeted delivery of drugs such as anticancer drugs, photodynamic drugs, anti-inflammatories, antivirals, antibacterials, nutraceuticals and metals with therapeutic and diagnostic properties. Successful CDs for the proposed technology are FDA-approved or in advanced pre-clinical investigational stage and include natural and functionalized, polymeric, and amphiphilic monomeric CDs. These are powders of freeze-dried CDs or CDs films from solvent evaporation to be resuspended in the presence of the drug to be trapped in biologically relevant aqueous media. The proposed technology is extensively demonstrated for both hydrophilic and hydrophobic drugs. The trapping of the drug in the CD nanostructures is achieved through green preparations in water with the use of low percentages of organic solvents and allows the obtaining of highly homogeneous aqueous dispersions.

Type of innovation
Product / process innovation in integration with an already existing technology
Description of innovative features / Competitive advantages

The innovativeness of the proposal lies in the achievement of medical devices through a process that uses matrices and green methods such as CDs, aqueous media (superpure water, buffers and culture broths commonly used in biological assays) and small quantities of organic solvents. In addition, the process makes it possible to choose, through predictive computational theoretical studies, the suitable CD for the types of drug to be trapped. Ultimately, the technology makes it possible to engineer a multifunctional device that releases the drug at the site of action in a controlled and targeted manner.

Reference market
Incremental innovation
Impacts on existing markets
Development stage
Prototype
TRL
4
5
Advantages
Product/process/service/technology optimization
Patentable technology
No
Patented technology
No
Publication of technology
Published
Technology validation/demonstration
External validation
Market positioning
Italian
European
International
Partner required
Enteprise
Public research center/university
Private research center
Cooperation in national /european / international project

Information
For more information and/or to be put in contact with the Research Team, please contact the Project Manager:

Barbara Angelini - Project Manager
CNR - Unità Valorizzazione della Ricerca
Phone number 06.49932415
E-mail barbara.angelini@cnr.it